Health Condition 1: H028- Other specified disorders of eyelid
Conditions
Interventions
Intervention1: Doxycycline 20 mg + Standard of care (Lid scrub, lid message) + Tear substitute (CMC 4 times daily) + low-dose Doxycycline (20 mg twice daily) for 2 months.: Doxycycline 20 mg + Standar
Sponsors
Dr Phulen Sarma
Eligibility
Inclusion criteria
Inclusion criteria: 1.Age 18?60 years. 2. Diagnosis of chronic MGD Based on clinical signs (meibomian gland expressibility, meibum quality, glandular atrophy) and symptoms (dry eye, grittiness, and irritation). 3.Symptom severity Moderate to severe MGD, as determined by the Ocular Surface Disease Index (OSDI) score and the Meibomian Gland Dysfunction Scale. 4.Willingness to comply Ability to comply with the study protocol, including the administration of oral medications and attending follow-up visits. 5.Informed consent Signed informed consent form, acknowledging the voluntary nature of participation and the potential risks involved.
Exclusion criteria
Exclusion criteria: 1.Presence of other ocular conditions: Active ocular infection, ocular surface disease (e.g., severe blepharitis, keratoconus), or any other significant eye disease that could confound study outcomes. 2.Severe systemic disease: Uncontrolled systemic conditions such as cardiovascular disease, liver disease, or autoimmune disorders that may interfere with the safe use of doxycycline. 3.Pregnancy or lactation: Women who are pregnant, planning to become pregnant, or breastfeeding during the study period. 4.Use of contraindicated medications: Current use of medications that interact with Doxycycline, such as anticoagulants, or use of other oral antibiotics for MGD in the past 30 days. 5.Allergy to Doxycycline: Known hypersensitivity or allergy to Doxycycline or other tetracycline-class antibiotics. 6.Recent ocular surgery or procedures: Any ocular surgery (e.g., cataract surgery) or eye procedure (e.g., punctal plugs) within the last 3 months. 7.Current use of topical steroids: Use of ocular steroids or other anti-inflammatory medications within 4 weeks prior to enrollments.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the efficacy of high versus low dose of Doxycycline on Tear Film Breakup Time (TBUT).Timepoint: Baseline 8 weeks 5 months 8 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To compare the safety of high versus low dose of Doxycycline among patients with Chronic Meibomian Gland Dysfunction. 2. To compare the efficacy of high versus low dose of Doxycycline on meibomian gland dysfunction score (MGD score). 3. To compare the efficacy of high versus low dose of Doxycycline on Ocular Surface Disease Index (OSDI) score. 4. To compare the efficacy of high versus low dose of Doxycycline on recurrence at 3 and 6 months after stopping of treatment 5. To compare the efficacy of high versus low dose of Doxycycline on Schirmer test readings. 6. To compare the efficacy of high versus low dose of Doxycycline Corneal staining score 7. To compare the efficacy of high versus low dose of Doxycycline on Tear fluid cytokine level (IL-1B). 8. To compare efficacy of high vs. low dose of Doxycycline on recurrence at 3 and 6 months after stopping of treatment.Timepoint: Baseline 8 weeks 5 months 8 months | — |
Countries
India
Contacts
Public ContactDr Phulen Sarma
AIIMS, Guwahati
Outcome results
None listed